A Phase 3 interventional study of JDP-205 Injection and Diphenhydramine in Acute Urticaria, sponsored by JDP Therapeutics, Inc.. Completed at 6 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-09.
Sponsored by JDP Therapeutics, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Urticaria with a site in Canada — 1 open to participants now, 2 under way, 1 of them phase 3. Urticaria · Canada.
Among the 13 studies in Urticaria with a site in Canada, this one is the 10th largest by enrollment, is one of 2 that started in 2013, is one of 4 in phase 3, and was the 2nd registered.
148 studies on the registry are indexed under Urticaria; 20 are open to participants now.
Browse Urticaria studies →1 of the 13 studies in Urticaria with a site in Canada is open now. Recruiting first, the newest first:
Pfizer · Sites in Canada, United States, Bulgaria and 7 more countries
Ages 18+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 12 Urticaria studies recruiting now, 3 (25%) set no upper age limit and 6 (50%) stop at 75 or younger; 6 take children under 18; 6 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 2 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 36 is below the median of 51 across 104 interventional studies indexed under Urticaria.
Median enrollment 182 across the 13 interventional studies. Of the 11 that completed or were terminated, 7 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 13 have an industry lead sponsor. The 6 most frequent:
JDP Therapeutics, Inc. is the lead sponsor of 4 studies on the registry; none are open to participants now.
JDP Therapeutics, Inc. has 4 studies filed under Urticaria — fewer than ten, so there is no comparison to draw.
1 of the studies in Urticaria with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07219615PfizerA Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults. | 2026-12-25 |
Add it to your calendar (.ics) → With an account.
Among the 13 studies in Urticaria with a site in Canada, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a multicenter, parallel group, randomized, double-blind pilot Phase III clinical study of JDP-205 (cetirizine) injection, versus diphenhydramine injection, 50 mg/mL (Benadryl or generic equivalent), in approximately 36 patients with acute urticaria requiring treatment in Hospital Emergency Departments, Urgent Care Centers and Allergy Clinics.
Multicenter, parallel group, randomized, double-blind pilot Phase III clinical study of JDP-205 (cetirizine) injection, versus diphenhydramine injection, 50 mg/mL (Benadryl or generic equivalent), in approximately 36 patients with acute urticaria requiring treatment in Hospital Emergency Departments, Urgent Care Centers and Allergy Clinics. This study will be conducted in 33 patient who either present themselves to the hospital emergency department, allergy clinic or urgent care centers with acute urticaria or developed acute urticaria following a allergen challenge at an allergy clinic.
Following informed consent, eligibility will be established, capturing baseline data including vitals, age, medical history, and medications taken prior to coming to the clinical study site. Following data collection, study subjects will be randomized in a 1:1 ratio to receive study drug of either cetirizine 10 mg IV or diphenhydramine, 50 mg IV. Baseline data including vital signs, the extent of urticaria and erythema, the severity of pruritus, and the level of sedation will be recorded prior to and at 1 hour and 2 hours post study drug administration, and at the time of "Readiness for Discharge". The actual time at which the investigator determines that the subject is ready for discharge (physically and mentally fit) from the study site will also be recorded. At these same time intervals, subjects will be asked to self-rate (recorded by study staff) severity of their pruritus and level of sedation (recorded by study staff).
Twenty-four hours following discharge from the study site, study staff will call the subject to ask them a few short questions to follow-up on the treatment of their acute urticaria. All adverse and serious adverse events experienced by the subjects following informed consent, and all data captured will be recorded in the source documents and/or case report forms.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients are eligible to be included in the study only if they meet all of the following criteria:
Inclusion Criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
JDP-205 Injection, 10 mg/mL, 1 mL
Drug: JDP-205 Injection
Diphenhydramine Injection, 50 mg/mL, 1 mL
Drug: Diphenhydramine
Cetirizine, 10mg/mL; a single 1.0 mL injection via intravenous (IV) push over a period of \~2 minutes
Also known as: Cetirizine, Quzyttir
Diphenhydramine Injection, 50 mg/mL; a single 1.0 mL injection via intravenous (IV) push over a period of \~2 minutes
Also known as: Benadryl, DPH
Extent of Urticaria/Erythema Score (Physician Assessment)
Extent of Urticaria/Erythema Score (Physician Assessment), capturing extent of urticaria/erythema, using the Body Chart (adopted from Burn Chart). Extent of Urticaria/Erythema Score is the average of the 2 scores: 1. Percentage of body area using the body chart (adopted from burn Chart) 0 = none, 1= mild (,25% body coverage), 2 = moderate (25-50% body coverage, 3 = Severe/intense .50% body coverage 2. Intensity of redness (adopted from PASI) 0 = none, 1 = mile (light pink) 2= moderate (pink), 3 =severe/intense (red)
Time frame: Baseline, 1 hour, 2 hour, Discharge (up to 4 hours)
Physician Pruritus Severity Score
Physician Pruritus Severity Score based on patient expression of severity of itchiness. 0= none 1 = Mild (patient expresses itchiness but tolerable, and does not scratch 2= moderate definite awareness, bothersome, intermittently scratch affected area 3= severe difficult to tolerate scratch vigorously
Time frame: Baseline, 1 hour, 2 hour, discharge or up to 4 hours post intervention, whichever came first
Patient Pruritis Severity Score
Patient Pruritis Severity Score based on severity of itching at time of assessment. How severly are your hives itching at the moment? 0 = none 1= mild minimal awareness easily tolerated 2 = moderate definite awareness quite bothersome 3= severe difficult to tolerate
Time frame: Baseline, 1 hour, 2 hour, discharge or up to 4 hours post intervention, whichever came first
Composite Acute Urticaria Score Change From Baseline
A composite acute urticaria score, the sum of Extent of urticaria/erythema score (Physician), Physician pruritis score and Patient pruritis severity score. A composite acute urticaria score which the sum of the above three parameters (i.e. 0-9) was calculated post hoc for each patient at each time point and then their score change from the baseline were compared between the two treatment groups. Higher values indicate a worse outcome.
Time frame: Baseline, 1 hour, 2 hour, Discharge (an average of 1 day)
Sedation Scores and Time to Readiness for Discharge
Time from study drug injection to time to readiness for discharge based on composite sedation score at readiness for discharge consist of Physician Sedation Score and Patient Sedation Score Physician Sedation Score Score ranged from 0 to 4 (0=min, 4=max) 0 = None (Patient is completely alert. Does not look tired at all), 1 = Mild (Patient sitting/lying comfortably, and looks tired), 2 = Moderate (Drowsy, with occasional eyes closing), 3 = Severe (Asleep, with eyes closed but responds to minor motor stimulation), 4 = Extremely Severe (Asleep; does not respond to minor motor stimulation) Patient Sedation Score Score ranged from 0 to 4 (0=min, 4=max) 0 = None (Not drowsy at all), 1 = Mild (Slightly drowsy), 2 = Moderate (Quite drowsy), 3 = Severe (Extremely drowsy), 4 = Extremely Severe (Asleep, cannot self-rate) Higher the sedation score = worse outcome A composite sedation score which is the sum of the two parameters.
Time frame: Assessed at discharge or up to 4 hours post intervention, whichever came first data at discharge reported.
Percentage of Patients Requiring Additional Medication
Percentage of Patients Requiring Additional Medication (Rescue Medication)
Time frame: Baseline, 1 hour, 2 hour, Discharge (an average of 1 day)
Sedation Scores and Time to Readiness for Discharge HH:MM
Time from study drug injection to time to readiness for discharge based on Physician and Patient Sedation Scores Physician Sedation Score: 0 = None 1 = Mild 2 = Moderate 3= Severe 4 = Extremely Severe Patient Sedation Score 0= None 1- Mild 2 = Moderate 3= Severe 4 = Extremely Severe Higher scores = worse outcome
Time frame: Assessed at discharge or up to 4 hours post intervention, whichever came first data at discharge reported.
Recruitment of patients who either present to Hospital Emergency Departments, allergy clinics or Urgent Care Centers with acute urticaria, or develop acute urticaria following allergen challenge at an Allergy Clinic.
| Milestone | Test Drug | Control |
|---|---|---|
| Started | 16 | 17 |
| Completed | 16 | 17 |
| Not completed | 0 | 0 |
| Milestone | Test Drug | Control |
|---|---|---|
| Started | 16 | 17 |
| Completed | 16 | 15 |
| Not completed | 0 | 2 |
| Withdrew: Lost to follow-up | 0 | 2 |
Extent of Urticaria/Erythema Score (Physician Assessment), capturing extent of urticaria/erythema, using the Body Chart (adopted from Burn Chart). Extent of Urticaria/Erythema Score is the average of the 2 scores: 1. Percentage of body area using the body chart (adopted from burn Chart) 0 = none, 1= mild (,25% body coverage), 2 = moderate (25-50% body coverage, 3 = Severe/intense .50% body coverage 2. Intensity of redness (adopted from PASI) 0 = none, 1 = mile (light pink) 2= moderate (pink), 3 =severe/intense (red)
| units on a scale | Test Drug | Control |
|---|---|---|
| Baseline | 1.91 ± 0.61 | 1.74 ± 0.89 |
| 1 Hour | 1.53 ± 0.74 | 1.12 ± 1.05 |
| 2 Hour | 0.89 ± 0.60 | 1.35 ± 1.03 |
| Discharge | 1.09 ± 0.55 | 0.97 ± 0.94 |
Physician Pruritus Severity Score based on patient expression of severity of itchiness. 0= none 1 = Mild (patient expresses itchiness but tolerable, and does not scratch 2= moderate definite awareness, bothersome, intermittently scratch affected area 3= severe difficult to tolerate scratch vigorously
| score on a scale | Test Drug | Control |
|---|---|---|
| Baseline Assessment | 2. (1. to 3.00) | 2.00 (0.00 to 3.00) |
| 1 hour Assessment | 1.0 (0.0 to 2.0) | 1. (0.0 to 2.) |
| 2 hour Assessment | 1.0 (0.0 to 2.0) | 1.0 (0.0 to 2.0) |
| Discharge Assessment | 1.0 (0.0 to 2.0) | 0.0 (0.0 to 2.0) |
Patient Pruritis Severity Score based on severity of itching at time of assessment. How severly are your hives itching at the moment? 0 = none 1= mild minimal awareness easily tolerated 2 = moderate definite awareness quite bothersome 3= severe difficult to tolerate
| score on a scale | Test Drug | Control |
|---|---|---|
| Baseline | 2.19 ± 0.66 | 2.24 ± 1.03 |
| 1 Hour | 0.56 ± 0.63 | 0.82 ± 1.01 |
| 2 Hour | 0.56 ± 0.53 | 0.90 ± 1.29 |
| Discharge | 0.50 ± 0.52 | 0.59 ± 1.06 |
A composite acute urticaria score, the sum of Extent of urticaria/erythema score (Physician), Physician pruritis score and Patient pruritis severity score. A composite acute urticaria score which the sum of the above three parameters (i.e. 0-9) was calculated post hoc for each patient at each time point and then their score change from the baseline were compared between the two treatment groups. Higher values indicate a worse outcome.
| score on a scale | Test Drug | Control |
|---|---|---|
| 1-Hour Assessment | -3.13 ± 1.41 | -3.26 ± 2.10 |
| 2-Hour Assessment | -4.28 ± 1.12 | -3.65 ± 2.21 |
| Discharge Assessment | -3.81 ± 1.12 | -3.82 ± 2.28 |
Time from study drug injection to time to readiness for discharge based on composite sedation score at readiness for discharge consist of Physician Sedation Score and Patient Sedation Score Physician Sedation Score Score ranged from 0 to 4 (0=min, 4=max) 0 = None (Patient is completely alert. Does not look tired at all), 1 = Mild (Patient sitting/lying comfortably, and looks tired), 2 = Moderate (Drowsy, with occasional eyes closing), 3 = Severe (Asleep, with eyes closed but responds to minor motor stimulation), 4 = Extremely Severe (Asleep; does not respond to minor motor stimulation) Patient Sedation Score Score ranged from 0 to 4 (0=min, 4=max) 0 = None (Not drowsy at all), 1 = Mild (Slightly drowsy), 2 = Moderate (Quite drowsy), 3 = Severe (Extremely drowsy), 4 = Extremely Severe (Asleep, cannot self-rate) Higher the sedation score = worse outcome A composite sedation score which is the sum of the two parameters.
| score on a scale | Test Drug | Control |
|---|---|---|
| Physician sedation score at Readiness for Discharge | 0.19 ± 0.40 | 0.35 ± 0.49 |
| Patient sedation score at Readiness for Discharge | 0.25 ± 0.45 | 0.71 ± 0.69 |
| Composite sedation score at Readiness for Discharge | 0.44 ± 0.81 | 1.06 ± 0.97 |
Percentage of Patients Requiring Additional Medication (Rescue Medication)
| Participants | Test Drug | Control |
|---|---|---|
| Rescue Required at Discharge ]Reported by HCP | 1 | 2 |
| Additional Rescue Required 24 Hours After Discharged as Reported by Patient | 10 | 13 |
Time from study drug injection to time to readiness for discharge based on Physician and Patient Sedation Scores Physician Sedation Score: 0 = None 1 = Mild 2 = Moderate 3= Severe 4 = Extremely Severe Patient Sedation Score 0= None 1- Mild 2 = Moderate 3= Severe 4 = Extremely Severe Higher scores = worse outcome
| Hours | Test Drug | Control |
|---|---|---|
| Sedation Scores and Time to Readiness for Discharge HH:MM | 1.65 ± 0.53 | 2.23 ± 1.20 |
Collected over Adverse events were collected from time of informed consent through the 24-hour follow-up *after discharge (an average of 36 hours). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Test Drug | 0/16 (0%) | 0/16 (0%) | 14/16 (87.5%) |
| Control | 0/17 (0%) | 0/17 (0%) | 12/17 (70.6%) |
| Event | Test Drug | Control |
|---|---|---|
| RashSkin and subcutaneous tissue disorders | 4/16 | 2/17 |
| Rash pruriticSkin and subcutaneous tissue disorders | 3/16 | 3/17 |
| PruritisSkin and subcutaneous tissue disorders | 3/16 | 1/17 |
| UrticariaSkin and subcutaneous tissue disorders | 2/16 | 2/17 |
| DizzinessNervous system disorders | 1/16 | 1/17 |
| SomnolenceNervous system disorders | 1/16 | 1/17 |
| Burning sensationGeneral disorders | 1/16 | 1/17 |
| HeadacheNervous system disorders | 1/16 | 0/17 |
| Abdominal discomfortGastrointestinal disorders | 1/16 | 0/17 |
| Lip swellingGastrointestinal disorders | 1/16 | 0/17 |
| Age, Categorical(Participants) | Test Drug | Control | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 15 | 17 | 32 |
| >=65 years | 1 | 0 | 1 |
| Age, Continuous(Years) | Test Drug | Control | Total |
|---|---|---|---|
| Mean | 36 ± 17 | 39 ± 14 | 37 ± 15 |
| Sex: Female, Male(Participants) | Test Drug | Control | Total |
|---|---|---|---|
| Female | 6 | 9 | 15 |
| Male | 10 | 8 | 18 |
| Region of Enrollment(participants) | Test Drug | Control | Total |
|---|---|---|---|
| Canada | 9 | 10 | 19 |
| United States | 7 | 7 | 14 |
Plan to share: No
No publications or documents are linked to this record.
The record gives a start of Jul 2013, a primary completion of Dec 2014 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2024, 9 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cetirizine
JDP Therapeutics, Inc.